Document And Entity Information
Document And Entity Information | 6 Months Ended |
Jun. 30, 2021 | |
Document Information Line Items | |
Entity Registrant Name | XTL Biopharmaceuticals Ltd. |
Document Type | 6-K |
Current Fiscal Year End Date | --12-31 |
Amendment Flag | false |
Entity Central Index Key | 0001023549 |
Document Period End Date | Jun. 30, 2021 |
Document Fiscal Year Focus | 2021 |
Document Fiscal Period Focus | Q2 |
Entity File Number | 001-36000 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Financial Position (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 2,918 | $ 3,631 |
Marketable securities – InterCure Ltd | 3,379 | 2,411 |
Prepaid expenses and other current assets | 274 | 79 |
Total current assets | 6,571 | 6,121 |
NON-CURRENT ASSETS: | ||
Fixed assets, net | 2 | 2 |
Intangible assets, net | 380 | 380 |
Non-current assets | 382 | 382 |
Total assets | 6,953 | 6,503 |
CURRENT LIABILITIES: | ||
Accounts payable | 258 | 254 |
NON-CURRENT LIABILITIES: | ||
Warrants | 3,413 | 2,637 |
EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY: | ||
Share capital - ordinary shares of NIS 0.1 par value: authorized - June 30, 2021 (unaudited) and December 31, 2020 - 1,450,000,000 shares; issued and outstanding: June 30, 2021 (unaudited) 528,156,149,and December 31, 2020 - 514,205,799 (audited) | 13,603 | 13,182 |
Additional paid in capital | 146,106 | 146,015 |
Reserve from transactions with non-controlling interests | 20 | 20 |
Accumulated deficit | (156,447) | (155,605) |
Total equity | 3,282 | 3,612 |
Total liabilities and equity | $ 6,953 | $ 6,503 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Financial Position (Unaudited) (Parentheticals) - ₪ / shares | Jun. 30, 2021 | Dec. 31, 2020 |
Statement of financial position [abstract] | ||
Ordinary shares, par value (in New Shekels per share) | ₪ 0.1 | ₪ 0.1 |
Ordinary shares, authorized | 1,450,000,000 | 1,450,000,000 |
Ordinary shares, issued | 528,156,149 | 514,205,799 |
Ordinary shares, outstanding | 528,156,149 | 514,205,799 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Profit or loss [abstract] | ||||
Research and development expenses | $ (6) | $ (11) | $ (18) | $ (14) |
General and administrative expenses | (297) | (206) | (517) | (460) |
Operating loss | (303) | (217) | (535) | (474) |
Revaluation of marketable securities - InterCure Ltd | (68) | (216) | 968 | 61 |
Revaluation of warrants to purchase ADS’s | (776) | (681) | (1,289) | (535) |
Other finance income | 3 | 13 | 5 | 25 |
Other finance expenses | (6) | (4) | (14) | (9) |
Finance expenses, net | (847) | (888) | (330) | (458) |
Total loss for the period | $ (1,150) | $ (1,105) | $ (865) | $ (932) |
Basic and diluted loss per share (in U.S. dollars): (in Dollars per share) | $ (0.002) | $ (0.002) | $ (0.002) | $ (0.002) |
Weighted average number of Ordinary Shares used in computing basic and diluted net loss per share (in Shares) | 527,794,273 | 514,205,799 | 522,758,917 | 514,205,799 |
Condensed Statements of Changes
Condensed Statements of Changes in Equity (Unaudited) - USD ($) $ in Thousands | Share capital | Additional paid in capital | Accumulated deficit | Reserve from transactions with non-controlling interests | Total |
Balance at Dec. 31, 2019 | $ 13,182 | $ 146,015 | $ (152,702) | $ 20 | $ 6,515 |
Loss for the period | (932) | (932) | |||
Share-based payment to employees and non-employees | 12 | 12 | |||
Balance at Jun. 30, 2020 | 13,182 | 146,015 | (153,622) | 20 | 5,595 |
Balance at Mar. 31, 2020 | 13,182 | 146,015 | (152,511) | 20 | 6,706 |
Loss for the period | (1,105) | (1,105) | |||
Share-based payment to employees and non-employees | (6) | (6) | |||
Balance at Jun. 30, 2020 | 13,182 | 146,015 | (153,622) | 20 | 5,595 |
Balance at Dec. 31, 2020 | 13,182 | 146,015 | (155,605) | 20 | 3,612 |
Loss for the period | (865) | (865) | |||
Exercise of warrants to ordinary shares | 421 | 91 | 512 | ||
Share-based payment to employees and non-employees | 23 | 23 | |||
Balance at Jun. 30, 2021 | 13,603 | 146,106 | (156,447) | 20 | 3,282 |
Balance at Mar. 31, 2021 | 13,574 | 146,080 | (155,307) | 20 | 4,367 |
Loss for the period | (1,150) | (1,150) | |||
Exercise of warrants to ordinary shares | 29 | 26 | 55 | ||
Share-based payment to employees and non-employees | 10 | 10 | |||
Balance at Jun. 30, 2021 | $ 13,603 | $ 146,106 | $ (156,447) | $ 20 | $ 3,282 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Cash flows from operating activities: | ||
Net loss for the period | $ (865) | $ (932) |
Adjustments to reconcile loss to net cash used in operating activities (a) | 148 | 481 |
Net cash used in operating activities | (717) | (451) |
Cash flows from investing activities: | ||
Interest from bank deposit | 5 | 24 |
Purchase of property and equipment | ||
Net cash from investing activities | 5 | 24 |
Cash flows from financing activities: | ||
Net cash provided by financing activities | ||
Decrease in cash and cash equivalents | (712) | (427) |
Gains from exchange rate differences on cash and cash equivalents | (1) | (1) |
Cash and cash equivalents at the beginning of the period | 3,631 | 4,455 |
Cash and cash equivalents at the end of the period | 2,918 | 4,027 |
Income and expenses not involving operating cash flows: | ||
Depreciation | 1 | |
Revaluation of marketable securities - InterCure Ltd | (968) | (61) |
Revaluation of warrants to purchase ADS’s | 1,289 | 535 |
Share-based payment transactions to employees and non-employees | 23 | 12 |
Gains from exchange rate differences on cash and cash equivalents | 1 | 1 |
Interest income | (5) | (24) |
Other financial expenses (income) | (1) | |
Net income and expenses not involving cash flows | 339 | 464 |
Changes in operating asset and liability items: | ||
Decrease (increase) in prepaid expenses and other current assets | (195) | 55 |
Increase (decrease) in other accounts payable | 4 | (38) |
Net operating asset and liability | (191) | 17 |
Net cash provided by (used in) operating activities | 148 | 481 |
(b) Non-cash activities: | ||
Exercise of warrants | $ 512 |
General
General | 6 Months Ended |
Jun. 30, 2021 | |
General [Abstract] | |
GENERAL | NOTE 1: GENERAL A general description of the Company and its activity: XTL Biopharmaceuticals Ltd. (the “Company”) is engaged in the development of therapeutics for the treatment of unmet medical needs. The Company was incorporated under the Israeli Companies Law on March 9, 1993. The registered office of the Company is located at 5 Badner Street, Ramat Gan, Israel. The Company’s American Depository Shares (“ADSs”) are listed for trading on the Nasdaq Capital Market (“Nasdaq”) and its ordinary shares are traded on the Tel-Aviv Stock Exchange (“TASE”). As of June 30, 2021, the Company has a wholly-owned subsidiary, Xtepo Ltd. (“Xtepo”), which was incorporated in Israel. The Company and Xtepo are heretofore referred to as the Group. |
Basis of Preparation of the Una
Basis of Preparation of the Unaudited Interim Consolidated Financial Statements | 6 Months Ended |
Jun. 30, 2021 | |
Disclosure of basis of preparation of financial statements [text block] [Abstract] | |
BASIS OF PREPARATION OF THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS | NOTE 2: BASIS OF PREPARATION OF THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS a. The condensed consolidated financial information of the Company as of June 30, 2021 and 2020, and for the respective interim periods of three months then ended (“interim financial information”) has been prepared in accordance with IAS 34, “Interim Financial Reporting” (“IAS 34”) and includes the additional disclosure requirements in accordance with Chapter D of the Israeli Securities Regulations (Periodic and Immediate Reports), 1970. This interim financial information does not contain all the information and disclosures that are required in the framework of the annual financial statements. This interim financial information should be read in conjunction with the annual financial statements for 2020 and the accompanying notes which have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board, and included the additional disclosure requirements in accordance with the Israeli Securities Regulations (Annual Financial Statements), 2010. b. Estimates - the preparation of the interim consolidated financial statements requires the Company’s management to make judgments and to use accounting estimates and assumptions that have an effect on the application of the Company’s accounting policies and on the reported amounts of assets, liabilities and expenses. Actual results could differ from those estimates. In the preparation of these interim consolidated financial statements, the significant judgment exercised by management in applying the Company’s accounting policies and the uncertainties involved in the key sources of the estimates were identical to those in the annual consolidated financial statements for the year ended December 31, 2020. |
Significant Accounting Policies
Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2021 | |
Significant Accounting Policies [Abstract] | |
SIGNIFICANT ACCOUNTING POLICIES | NOTE 3: SIGNIFICANT ACCOUNTING POLICIES The Company’s significant accounting policies and methods of computation adopted in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the annual consolidated financial statements for 2020. |
Significant Events During The P
Significant Events During The Period | 6 Months Ended |
Jun. 30, 2021 | |
Disclosure of non-adjusting events after reporting period [line items] | |
SIGNIFICANT EVENTS DURING THE PERIOD | NOTE 4: SIGNIFICANT EVENTS DURING THE PERIOD COVID-19 virus The outbreak of the Coronavirus in the world in the first half of 2020 and its spread, causes great uncertainty in the world capital markets and major macroeconomic implications, which are characterized by sharp declines and volatility in many securities’ prices. As of the date of issuance of the financial reporting, there was no material effect of the Coronavirus on the operations and financial results of the Company. Although, due to the ongoing uncertainty around the scope and duration of the Coronavirus, as of the financial statement publication date, there is uncertainty regarding its impact on the economy and the market state at all, and those impacts on the value of the securities held by the Company. The Company is monitoring and will continue to monitor the developments around the world in connection with the spread of the Coronavirus, and will examine the implications for its activities. |
Restatement
Restatement | 6 Months Ended |
Jun. 30, 2021 | |
Disclosure Of Restatementtext Block [Abstract] | |
RESTATEMENT | NOTE 5: RESTATEMENT Restatement of previously issued consolidated financial statements In March 2018 the Company’s warrants were allocated to share premium as a result of its cancellation of the cashless exercise mechanism. During the second quarter of 2021, the Company concluded that the cashless exercise mechanism was not in fact cancelled when the registration statement published in March 2018 became ineffective, as a result of which the right to exercise the warrants on a cashless basis was possible, resulting in the situation that the warrants should have remained a non-current liability, and not an equity instrument. The financial statements of 2020 were restated and published on May 13, 2021. The impacts of the error in the warrant classification are as follows: Impact on the consolidated statement of comprehensive income (loss): Six months ended 2020 As previously reported As restated Adjustments U.S. dollars in thousands Revaluation of warrants to purchase ADS’s - 535 535 Finance income (expenses), net 77 (458 ) 535 Total comprehensive income (loss) for the year (397 ) (932 ) 535 Basic and diluted earnings (loss) per share (in U.S. dollars): (0.001 ) (0.002 ) (0.001 ) Three months ended 2020 As previously reported As restated Adjustments U.S. dollars in thousands Revaluation of warrants to purchase ADS’s - 681 681 Finance income (expenses), net (207 ) (888 ) 681 Total comprehensive income (loss) for the year (424 ) (1,105 ) 681 Basic and diluted earnings (loss) per share (in U.S. dollars): (0.001 ) (0.002 ) (0.001 ) Impact on the consolidated statements of financial position: June 30, 2020 As previously reported As restated Adjustments U.S. dollars in thousands Non-current liabilities - 1,000 1,000 Additional paid in capital 147,708 146,015 (1,693 ) Accumulated deficit (154,315 ) (153,622 ) 693 Total equity 6,595 5,595 (1,000 ) |
Marketable Securities _ InterCu
Marketable Securities – InterCure Ltd | 6 Months Ended |
Jun. 30, 2021 | |
Marketable Securities - InterCure Ltd [Abstract] | |
MARKETABLE SECURITIES – InterCure Ltd | NOTE 6: MARKETABLE SECURITIES – InterCure Ltd a. All marketable securities held by the Company constitute Level 1 financial instruments, as defined in IFRS 13 - “ Fair Value Measurement b. The Company holds the following financial instruments: June 30, December 31, 2021 2020 U.S. dollars in thousands Marketable securities – InterCure Ltd 3,379 2,411 The entire investment in marketable securities is classified as a financial asset at fair value through profit or loss. As of December 31, 2020 the Company holds approximately 1.76% of InterCure Ltd’s shares (the shares are traded at the Tel-Aviv Stock Exchange - “TASE”). c. Changes in marketable securities for the six months ended June 30, 2021 and the year ended December 31, 2020 were all from changes in the fair value (no sales occurred). |
Warrants
Warrants | 6 Months Ended |
Jun. 30, 2021 | |
Warrants At Fair Value Of Explanatory [Abstract] | |
WARRANTS | NOTE 7: WARRANTS During the year ended December 31, 2017, the Company raised gross funds amounted to $5,300 thousand by issuance of 2,400,000 ADS’s and 2,450,000 warrants to purchase the same amount of ADS’s. The warrants shall be exercisable six months following the issuance date and will expire five and one-half years from the issuance date. The number of warrants and their exercise price could be adjusted upon standard anti-dilution protection clauses and subject to a cashless exercise mechanism (see also Note 13d). IFRS 13 “Fair Value Measurement”, (“IFRS 13”), defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. IFRS 13 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. IFRS 13 establishes three levels of inputs that may be used to measure fair value. Level 1 - quoted prices in active markets for identical assets or liabilities; Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company accounted for the warrants issued to investors with a cashless exercise mechanism as a non-current liability according to provisions of IAS 32. The Company measured the warrants at fair value by using a Black and Scholes model. The warrants were measured in each reporting period. Changes in the fair value were recognized in the Company’s statement of comprehensive income (loss) as financial income or expense, as appropriate. The warrants were classified as level 3. The Company used the following assumptions to estimate the Investors’ warrants: June 30, December 31, 2021 2020 2020 Risk-free interest rate (1) 0.10-0.11 % 0.15-0.16 % 0.12 % Expected volatility (2) 65.44-70.62 % 75.01-75.66 % 68.59-69.23 % Contractual term life (in years) (3) 1.13-1.18 2.13-2.18 1.63-1.68 Dividend yield (4) 0 % 0 % 0 % (1) Risk-free interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds. (2) Expected volatility - was calculated based on actual historical share price movements of the Company over a term that is equivalent to the contractual term of the option. (3) Expected life - the expected life was based on the expiration date of the warrants. (4) Dividend yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends to its shareholders in the future. Outstanding warrants: The table below summarizes the outstanding warrants as of June 30, 2021: Warrants Number of Issuance Exercise price in USD Expiration date 650,000 65,000,000 February 17, 2017 4.1 August 16, 2022 1,365,000 136,500,000 March 7, 2017 2.3 September 6, 2022 2,015,000 201,500,000 In March 2021, as a result of a cashless exercise of warrants by an investor from the February 2017 offering, the Company issued 12,981,800 ordinary shares represented by 129,818 ADSs. In April 2021, as a result of a cashless exercise of warrants by an investor from the March 2017 offering, the Company issued 968,550 ordinary shares represented by 9,685 ADSs. |
Transactions With Related Parti
Transactions With Related Parties | 6 Months Ended |
Jun. 30, 2021 | |
Disclosure of Transactions with Related Parties [Abstract] | |
TRANSACTIONS WITH RELATED PARTIES | NOTE 8: TRANSACTIONS WITH RELATED PARTIES “Related party” - as the term is defined in IAS 24, “Related Party Disclosures” The Company’s key management personnel who are included, along with other factors, in the definition of related party, as above in IAS 24, includes directors, members of the executive committee and InterCure Ltd. Compensation to key management personnel: The compensation to key management personnel for employee services provided to the Company is shown below: Six months ended 30, Year ended December 31, 2021 2020 2020 U.S. dollars in thousands Salaries, management and consulting fees and other short-term benefits 122 159 276 Pension, post retirement and other benefits - 2 2 Share-based payments 23 12 51 145 173 329 Number of persons 8 8 8 InterCure Ltd: The Company’s investment in the shares of InterCure Ltd is presented as Marketable securities (See note 6 for additional information). The Company subleases an office from Canndoc Ltd, which is a subsidiary of InterCure Ltd. During the six months ended June. 2021 approximately $7 thousands were paid to Canndoc Ltd for the rent (during the year 2020 approximately $20 thousands). As of June 30,2021, June 30,2020 and December 31, 2020, the Company’s share in the shares of InterCure Ltd was 1.11%, 1.94% and 1.76%, respectively. |
Subsequent Events
Subsequent Events | 6 Months Ended |
Jun. 30, 2021 | |
Disclosure of Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | NOTE 9: SUBSEQUENT EVENTS In July 2021, as a result of exercises of warrants by two investors from the February 2017 offering, the Company issued 8,500,000 ordinary shares represented by 85,000 ADSs, in return to $195,500 (the exercise price, $2.3 per ADS). |
Restatement (Tables)
Restatement (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Disclosure Of Restatementtext Block [Abstract] | |
Schedule of impact on the consolidated statement of comprehensive income (loss) | Six months ended 2020 As previously reported As restated Adjustments U.S. dollars in thousands Revaluation of warrants to purchase ADS’s - 535 535 Finance income (expenses), net 77 (458 ) 535 Total comprehensive income (loss) for the year (397 ) (932 ) 535 Basic and diluted earnings (loss) per share (in U.S. dollars): (0.001 ) (0.002 ) (0.001 ) Three months ended 2020 As previously reported As restated Adjustments U.S. dollars in thousands Revaluation of warrants to purchase ADS’s - 681 681 Finance income (expenses), net (207 ) (888 ) 681 Total comprehensive income (loss) for the year (424 ) (1,105 ) 681 Basic and diluted earnings (loss) per share (in U.S. dollars): (0.001 ) (0.002 ) (0.001 ) |
Schedule of impact on the consolidated statements of financial position | June 30, 2020 As previously reported As restated Adjustments U.S. dollars in thousands Non-current liabilities - 1,000 1,000 Additional paid in capital 147,708 146,015 (1,693 ) Accumulated deficit (154,315 ) (153,622 ) 693 Total equity 6,595 5,595 (1,000 ) |
Marketable Securities _ Inter_2
Marketable Securities – InterCure Ltd (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Disclosure Of Marketable Securities Explanatory [Abstract] | |
Schedule of financial instruments | June 30, December 31, 2021 2020 U.S. dollars in thousands Marketable securities – InterCure Ltd 3,379 2,411 |
Warrants (Tables)
Warrants (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Warrants At Fair Value Of Explanatory [Abstract] | |
Schedule of warrants valuation assumptions of investors' warrants | June 30, December 31, 2021 2020 2020 Risk-free interest rate (1) 0.10-0.11 % 0.15-0.16 % 0.12 % Expected volatility (2) 65.44-70.62 % 75.01-75.66 % 68.59-69.23 % Contractual term life (in years) (3) 1.13-1.18 2.13-2.18 1.63-1.68 Dividend yield (4) 0 % 0 % 0 % (1) Risk-free interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds. (2) Expected volatility - was calculated based on actual historical share price movements of the Company over a term that is equivalent to the contractual term of the option. (3) Expected life - the expected life was based on the expiration date of the warrants. (4) Dividend yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends to its shareholders in the future. |
Schedule of outstanding warrants | Warrants Number of Issuance Exercise price in USD Expiration date 650,000 65,000,000 February 17, 2017 4.1 August 16, 2022 1,365,000 136,500,000 March 7, 2017 2.3 September 6, 2022 2,015,000 201,500,000 |
Transactions With Related Par_2
Transactions With Related Parties (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Disclosure of related party [text block] [Abstract] | |
Schedule of compensation to key management personnel for employee services | Six months ended 30, Year ended December 31, 2021 2020 2020 U.S. dollars in thousands Salaries, management and consulting fees and other short-term benefits 122 159 276 Pension, post retirement and other benefits - 2 2 Share-based payments 23 12 51 145 173 329 Number of persons 8 8 8 |
Restatement (Details) - Schedul
Restatement (Details) - Schedule of impact on the consolidated statement of comprehensive income (loss) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended |
Jun. 30, 2020 | Jun. 30, 2020 | |
As previously reported [Member] | ||
Restatement (Details) - Schedule of impact on the consolidated statement of comprehensive income (loss) [Line Items] | ||
Revaluation of warrants to purchase ADS’s | ||
Finance income (expenses), net | (207) | 77 |
Total comprehensive income (loss) for the year | $ (424) | $ (397) |
Basic and diluted earnings (loss) per share (in U.S. dollars) (in Dollars per share) | $ (0.001) | $ (0.001) |
As restated [Member] | ||
Restatement (Details) - Schedule of impact on the consolidated statement of comprehensive income (loss) [Line Items] | ||
Revaluation of warrants to purchase ADS’s | $ 681 | $ 535 |
Finance income (expenses), net | (888) | (458) |
Total comprehensive income (loss) for the year | $ (1,105) | $ (932) |
Basic and diluted earnings (loss) per share (in U.S. dollars) (in Dollars per share) | $ (0.002) | $ (0.002) |
Adjustments [Member] | ||
Restatement (Details) - Schedule of impact on the consolidated statement of comprehensive income (loss) [Line Items] | ||
Revaluation of warrants to purchase ADS’s | $ 681 | $ 535 |
Finance income (expenses), net | 681 | 535 |
Total comprehensive income (loss) for the year | $ 681 | $ 535 |
Basic and diluted earnings (loss) per share (in U.S. dollars) (in Dollars per share) | $ (0.001) | $ (0.001) |
Restatement (Details) - Sched_2
Restatement (Details) - Schedule of impact on the consolidated statements of financial position $ in Thousands | Jun. 30, 2020USD ($) |
As previously reported [Member] | |
Restatement (Details) - Schedule of impact on the consolidated statements of financial position [Line Items] | |
Non-current liabilities | |
Additional paid in capital | 147,708 |
Accumulated deficit | (154,315) |
Total equity | 6,595 |
As restated [Member] | |
Restatement (Details) - Schedule of impact on the consolidated statements of financial position [Line Items] | |
Non-current liabilities | 1,000 |
Additional paid in capital | 146,015 |
Accumulated deficit | (153,622) |
Total equity | 5,595 |
Adjustments [Member] | |
Restatement (Details) - Schedule of impact on the consolidated statements of financial position [Line Items] | |
Non-current liabilities | 1,000 |
Additional paid in capital | (1,693) |
Accumulated deficit | 693 |
Total equity | $ (1,000) |
Marketable Securities _ Inter_3
Marketable Securities – InterCure Ltd (Details) | 12 Months Ended |
Dec. 31, 2020 | |
Disclosure Of Marketable Securities Explanatory [Abstract] | |
Percentage of shares hold | 1.76% |
Marketable Securities _ Inter_4
Marketable Securities – InterCure Ltd (Details) - Schedule of financial instruments - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Schedule of financial instruments [Abstract] | ||
Marketable securities – InterCure Ltd | $ 3,379 | $ 2,411 |
Warrants (Details)
Warrants (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended | |
Apr. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2017 | |
Warrants (Details) [Line Items] | |||
Gross funds raised (in Dollars) | $ 5,300 | ||
Warrants issued | 2,450,000 | ||
Description of warrants exercisable | The warrants shall be exercisable six months following the issuance date and will expire five and one-half years from the issuance date. | ||
Issuance of offering date | March 2017 | February 2017 | |
Number of ordinary shares issued | 968,550 | 12,981,800 | |
American Depository Shares [Member] | |||
Warrants (Details) [Line Items] | |||
Warrants issued | 2,400,000 | ||
Number of ADSs issued | 9,685 | 129,818 |
Warrants (Details) - Schedule o
Warrants (Details) - Schedule of warrants valuation assumptions of investors' warrants | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | ||
Warrants (Details) - Schedule of warrants valuation assumptions of investors' warrants [Line Items] | ||||
Risk-free interest rate | [1] | 0.12% | ||
Dividend yield | [2] | 0.00% | 0.00% | 0.00% |
Bottom of Range [Member] | ||||
Warrants (Details) - Schedule of warrants valuation assumptions of investors' warrants [Line Items] | ||||
Risk-free interest rate | [1] | 0.10% | 0.15% | |
Expected volatility | [3] | 65.44% | 75.01% | 68.59% |
Contractual term life (in years) | [4] | 1 year 1 month 17 days | 2 years 1 month 17 days | 1 year 7 months 17 days |
Top of Range [Member] | ||||
Warrants (Details) - Schedule of warrants valuation assumptions of investors' warrants [Line Items] | ||||
Risk-free interest rate | [1] | 0.11% | 0.16% | |
Expected volatility | [3] | 70.62% | 75.66% | 69.23% |
Contractual term life (in years) | [4] | 1 year 2 months 4 days | 2 years 2 months 4 days | 1 year 8 months 4 days |
[1] | Risk-free interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds. | |||
[2] | Dividend yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends to its shareholders in the future. | |||
[3] | Expected volatility - was calculated based on actual historical share price movements of the Company over a term that is equivalent to the contractual term of the option. | |||
[4] | Expected life - the expected life was based on the expiration date of the warrants. |
Warrants (Details) - Schedule_2
Warrants (Details) - Schedule of outstanding warrants | 6 Months Ended |
Jun. 30, 2021$ / sharesshares | |
Warrants (Details) - Schedule of outstanding warrants [Line Items] | |
Warrants outstanding to purchase ADSs | 2,015,000 |
Number of shares exercisable | 201,500,000 |
February 17, 2017 [Member] | |
Warrants (Details) - Schedule of outstanding warrants [Line Items] | |
Warrants outstanding to purchase ADSs | 650,000 |
Number of shares exercisable | 65,000,000 |
Issuance date | Feb. 17, 2017 |
Exercise price in USD (per warrant) (in Dollars per share) | $ / shares | $ 4.1 |
Expiration date | Aug. 16, 2022 |
March 7, 2017 [Member] | |
Warrants (Details) - Schedule of outstanding warrants [Line Items] | |
Warrants outstanding to purchase ADSs | 1,365,000 |
Number of shares exercisable | 136,500,000 |
Issuance date | Mar. 7, 2017 |
Exercise price in USD (per warrant) (in Dollars per share) | $ / shares | $ 2.3 |
Expiration date | Sep. 6, 2022 |
Transactions With Related Par_3
Transactions With Related Parties (Details) - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | |
Transactions with Related Parties [Abstract] | |||
Company's share in the shares of InterCure Ltd | 1.11% | 1.94% | 1.76% |
Canndoc Ltd [Member] | |||
Transactions with Related Parties [Abstract] | |||
Rent payments (in Dollars) | $ 7 | $ 20 |
Transactions With Related Par_4
Transactions With Related Parties (Details) - Schedule of compensation to key management personnel for employee services $ in Thousands | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2021USD ($) | Jun. 30, 2020USD ($) | Dec. 31, 2020USD ($) | |
Schedule of compensation to key management personnel for employee services [Abstract] | |||
Salaries, management and consulting fees and other short-term benefits | $ 122 | $ 159 | $ 276 |
Pension, post retirement and other benefits | 2 | 2 | |
Share-based payments | 23 | 12 | 51 |
Total compensation expense | $ 145 | $ 173 | $ 329 |
Number of persons | 8 | 8 | 8 |
Subsequent Events (Details)
Subsequent Events (Details) - Subsequent Event [Member] | 1 Months Ended |
Jul. 31, 2021USD ($)$ / sharesshares | |
Subsequent Events (Details) [Line Items] | |
Number of investors | 2 |
Offering date | February 2017 |
Issue of ordinary shares | 8,500,000 |
Issued capital (in Dollars) | $ | $ 195,500 |
American Depository Shares [Member] | |
Subsequent Events (Details) [Line Items] | |
Number of ADSs issued | 85,000 |
Exercise price, per share (in Dollars per share) | $ / shares | $ 2.3 |